That said, this does not imply there won’t be any future opportunities.

A sustained double digit share price would be an example of said 'future opportunities', imo, satisfying the market cap requirement for a listing.

With a second BTD, which I expect within the next couple of months, I would find it inconceivable that we wouldn't be well into double digits.  The Seeking Alpha article studied the market cap values of single-BTD companies and found $8B US as the average market cap.  Higher valuations for BTD for indications in large patient populations - which we certainly have.  Remember, a $10B US valuation for RVX equates to a CAD $52 share price.  

I just can`t see how a company with Multi-BTDs in massive indications  can remain unnoticed and unbidded for, for very long anyway.  In this environment the SP should be plenty high enough for a listing.  The next few months should prove exciting.  GLTA

JMHO